Champignon Closes AltMed Transaction, Partners With Leading Canadian Pharmacy

Champignon Brands (CSE: SHRM) today announced that it has partnered with a major pharmacy chain within Canada to dispense its ketamine topical prescription product throughout the network. While the pharmacy chain was not addressed by name, it is said to be one of the leading chains within the country.

Under the arrangement, Champignon will see the pharmacy perform central fill and compounding functions for the firms proprietary ketamine formulations at one location. The products will then be distributed as needed throughout the pharmacies network of locations. Champignon will be utilizing this network to also distribute its products to numerous medical and pain and addiction clinics throughout the nation.

In connection with the arrangement, Champignon and the pharmacy have begun to design a custom level “B” clean room which will be used to compound and package the ketamine formulations, which is expected to be completed by the third quarter of 2020. Such formulations include off-market intranasal esketamine and ketamine topicals.

“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies. From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle.”
Gareth Bridsall, CEO

Outside the developments of Champignon’s ketamine formulations, the company also announced that it has closed the transaction with that of AltMed Capital Corp. AltMed operates a ketamine clinic in Ontario known as the Canadian Rapid Treatment Centre of Excellence (CRTCE), for which it recently acquired 100% of, in addition to being a psychedelic medicine IP aggregator and novel drug discoverer.

Champignon currently intends to open five additional ketamine clinics across North America by the fourth quarter of 2020, with locations planned for New York, California, and Florida.

Champignon Brands last traded at $0.88 on the CSE.


FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

This Could Be the Next Multi-Million Ounce Gold Camp | Mike Bennett

Newmont Stock Drops Despite Massive Cash Flow — Here’s Why | Q4 Earnings

Strongest Gold Bull Market in 30 Years — And It’s Global | Michael Dehn

Recommended

Advanced Gold Acquires Nevada Property With Historic Production At 1,611 g/t Silver

Steadright: Atrium Research Initiates Coverage With $0.50 Price Target

Related News

Champignon Brands Announces Voluntary Share Lockup Agreement

Champignon Brands (CSE: SHRM) this morning announced that certain of the firms shareholders have agreed...

Friday, May 29, 2020, 08:23:52 AM

Champignon Brands To Acquire Biotech Firm Novo Formulations

Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire...

Thursday, March 19, 2020, 03:27:32 PM

Champignon Brands Files Required Disclosures With Exchange, Resumption Of Trading In Hands Of BCSC

Champignon Brands (CSE: SHRM) has completed the regulatory filings required as per the review previously...

Friday, July 24, 2020, 05:33:15 PM

Champignon Brands Latest Shroom Stock To IPO

Champignon Brands (CSE: SHRM) completed its initial public offering (IPO) late Friday night, with the...

Monday, March 2, 2020, 10:40:37 AM

Harvest Moon: Reducing Suicidal Ideation With Ketamine Infusions

Suicidal ideation is an emergent condition that demands immediate attention. It has been shown that...

Tuesday, May 26, 2020, 03:00:00 PM